At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 16 enrolled

Drug / intervention

Gabapentin +1 moredrug

Likely dose

Gabapentin 100 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02330094

NCT02330094Phase 4Completed

Compare CT.gov

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

Mayo Clinic·interventional·Posted Jan 1, 2015·Updated Sep 10, 2019

In Brief

A Phase 4 clinical trial evaluating Gabapentin and Placebo for Aneurysmal Subarachnoid Hemorrhage. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAneurysmal Subarachnoid Hemorrhage

CountriesUnited States

Collaborators--

Timeline

Phase 4CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartDec 2014

First PostedJan 2015

Primary CompletionSep 2017

TodayJul 2026

First PostedJan 1, 2015

Enrollment StartDec 1, 2014

Primary CompletionSep 1, 2017

TodayJul 2, 2026

Enrollment to primary: 2.8 yearsPosted 11.5 years ago

Interventions

Gabapentindrug

Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance. Both groups will receive other standard of care pain medications.

Placebodrug

Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance. Both groups will receive other standard of care pain medications.